TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers
Abstract Poor survival and lack of treatment response in glioblastoma (GBM) is attributed to the persistence of glioma stem cells (GSCs). To identify novel therapeutic approaches, we performed CRISPR/Cas9 knockout screens and discovered TGFβ activated kinase (TAK1) as a selective survival factor in...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2024-04-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-024-06654-1 |